Atlas Trials

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

Clinical trial NCT03386162 · TERMINATED

Trial details

NCT number
NCT03386162
Sponsor
UNICANCER
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer, PI3K, Alpelisib
Start date
2018-03-15
Primary completion
2022-11-18
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.